Riccardo Lencioni is Associate Professor of Radiology in the Department of Oncology, Transplants and Advanced Technologies in Medicine at the University of Pisa, Italy. He has an active role in several scientific societies, including the ECR, EAR and ESGAR. Professor Lencioni is also an Editorial Board member for European Radiology and Investigative Radiology and is a reviewer for a number of other titles including Abdominal Imaging, Cardiovascular and Interventional Radiology, Cancer, Gastroenterology, Hepatology, Digestive and Liver Disease, and Oncology. He has authored 96 original articles in peer-reviewed international journals, more than 50 book chapters, and four books. Riccardo Lencioni has also been invited to lecture at over 200 international meetings.

Abstract
Radiofrequency ablation (RFA) is a minimally invasive technique used to treat solid tumours. Following recent technological advances, RFA has gained an increasingly important role in the treatment of unresectable hepatic malignancies, and is challenging partial hepatectomy as the treatment of choice for patients with limited hepatic tumours. Although RFA of non-hepatic malignant tumours is at an early stage of clinical application, recent studies have shown that this technique could offer a valuable treatment option for lung, bone and renal malignancies. This article reviews the current status of RFA, with a focus on the treatment of liver and lung tumours.